Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model

Rajeth Koneru, Heather Bimonte-Nelson, Vincent Ciavatta, Woldeab Haile, Kate Elmore, Jennifer Ward, Leonard Maroun, William R. Tyor

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Increased brain interferon-alpha (IFN) is associated with neurodegenerative disorders, including HIV-associated neurocognitive disorders (HAND). HAND occurs in approximately 50% of individuals with HIV despite combined antiretroviral therapy (cART). Therefore, adjunctive therapies must be developed that prevent progression of mild forms of HAND to HIV-associated dementia. Increased IFN in the CNS has been associated with HAND in patients and in a HAND mouse model. Design and methods: B18R binds IFN and ameliorates HAND mouse brain histopathology (HIV encephalitis). The HAND model was used to determine if B18R with cART is superior to cART. Behavioral testing [Object recognition Test (ORT)] was used to show that B18R can reverse behavioral deficits. Rat neuronal cultures were used to investigate mechanisms of IFN neurotoxicity. Results: Mouse brain immunohistochemistry and densitometry suggests that B18R with a common cART regimen improve histopathological markers better than cART alone. B18R reverses ORT behavioral abnormalities in HAND mice. IFN-treated rat neurons show decreases in PSD-95, suggesting that dendritic spine architecture is disrupted. Decreases in Arf1, a GTP-binding protein, and AMPA receptors on the surface of rat neurons exposed to IFN suggest the mechanism of IFN neurotoxicity may relate to decreased Arf1 resulting in destabilization of dendritic spines, decreased PSD-95 expression, and internalization of AMPA receptors. Conclusion: B18R reversal of HAND in the mouse model is further evidence that the treatment of IFN in individuals with HAND could be a viable adjunctive treatment. Investigating pathways of IFN neurotoxicity may lead to more specific treatments.

Original languageEnglish (US)
Pages (from-to)1403-1411
Number of pages9
JournalAIDS
Volume32
Issue number11
DOIs
StatePublished - Jul 17 2018

Fingerprint

Interferon-alpha
HIV
Dendritic Spines
AMPA Receptors
Therapeutics
Neurocognitive Disorders
Brain
AIDS Dementia Complex
Neurons
Densitometry
Encephalitis
GTP-Binding Proteins
Neurodegenerative Diseases
Immunohistochemistry

Keywords

  • dendrites
  • HIV-associated neurocognitive disorders
  • interferon-alpha
  • mouse model
  • rat neuronal cultures
  • treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model. / Koneru, Rajeth; Bimonte-Nelson, Heather; Ciavatta, Vincent; Haile, Woldeab; Elmore, Kate; Ward, Jennifer; Maroun, Leonard; Tyor, William R.

In: AIDS, Vol. 32, No. 11, 17.07.2018, p. 1403-1411.

Research output: Contribution to journalArticle

Koneru, R, Bimonte-Nelson, H, Ciavatta, V, Haile, W, Elmore, K, Ward, J, Maroun, L & Tyor, WR 2018, 'Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model', AIDS, vol. 32, no. 11, pp. 1403-1411. https://doi.org/10.1097/QAD.0000000000001836
Koneru, Rajeth ; Bimonte-Nelson, Heather ; Ciavatta, Vincent ; Haile, Woldeab ; Elmore, Kate ; Ward, Jennifer ; Maroun, Leonard ; Tyor, William R. / Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model. In: AIDS. 2018 ; Vol. 32, No. 11. pp. 1403-1411.
@article{f3ebac0306a34af69eda4bcf1da9af08,
title = "Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model",
abstract = "Objective: Increased brain interferon-alpha (IFN) is associated with neurodegenerative disorders, including HIV-associated neurocognitive disorders (HAND). HAND occurs in approximately 50{\%} of individuals with HIV despite combined antiretroviral therapy (cART). Therefore, adjunctive therapies must be developed that prevent progression of mild forms of HAND to HIV-associated dementia. Increased IFN in the CNS has been associated with HAND in patients and in a HAND mouse model. Design and methods: B18R binds IFN and ameliorates HAND mouse brain histopathology (HIV encephalitis). The HAND model was used to determine if B18R with cART is superior to cART. Behavioral testing [Object recognition Test (ORT)] was used to show that B18R can reverse behavioral deficits. Rat neuronal cultures were used to investigate mechanisms of IFN neurotoxicity. Results: Mouse brain immunohistochemistry and densitometry suggests that B18R with a common cART regimen improve histopathological markers better than cART alone. B18R reverses ORT behavioral abnormalities in HAND mice. IFN-treated rat neurons show decreases in PSD-95, suggesting that dendritic spine architecture is disrupted. Decreases in Arf1, a GTP-binding protein, and AMPA receptors on the surface of rat neurons exposed to IFN suggest the mechanism of IFN neurotoxicity may relate to decreased Arf1 resulting in destabilization of dendritic spines, decreased PSD-95 expression, and internalization of AMPA receptors. Conclusion: B18R reversal of HAND in the mouse model is further evidence that the treatment of IFN in individuals with HAND could be a viable adjunctive treatment. Investigating pathways of IFN neurotoxicity may lead to more specific treatments.",
keywords = "dendrites, HIV-associated neurocognitive disorders, interferon-alpha, mouse model, rat neuronal cultures, treatment",
author = "Rajeth Koneru and Heather Bimonte-Nelson and Vincent Ciavatta and Woldeab Haile and Kate Elmore and Jennifer Ward and Leonard Maroun and Tyor, {William R.}",
year = "2018",
month = "7",
day = "17",
doi = "10.1097/QAD.0000000000001836",
language = "English (US)",
volume = "32",
pages = "1403--1411",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model

AU - Koneru, Rajeth

AU - Bimonte-Nelson, Heather

AU - Ciavatta, Vincent

AU - Haile, Woldeab

AU - Elmore, Kate

AU - Ward, Jennifer

AU - Maroun, Leonard

AU - Tyor, William R.

PY - 2018/7/17

Y1 - 2018/7/17

N2 - Objective: Increased brain interferon-alpha (IFN) is associated with neurodegenerative disorders, including HIV-associated neurocognitive disorders (HAND). HAND occurs in approximately 50% of individuals with HIV despite combined antiretroviral therapy (cART). Therefore, adjunctive therapies must be developed that prevent progression of mild forms of HAND to HIV-associated dementia. Increased IFN in the CNS has been associated with HAND in patients and in a HAND mouse model. Design and methods: B18R binds IFN and ameliorates HAND mouse brain histopathology (HIV encephalitis). The HAND model was used to determine if B18R with cART is superior to cART. Behavioral testing [Object recognition Test (ORT)] was used to show that B18R can reverse behavioral deficits. Rat neuronal cultures were used to investigate mechanisms of IFN neurotoxicity. Results: Mouse brain immunohistochemistry and densitometry suggests that B18R with a common cART regimen improve histopathological markers better than cART alone. B18R reverses ORT behavioral abnormalities in HAND mice. IFN-treated rat neurons show decreases in PSD-95, suggesting that dendritic spine architecture is disrupted. Decreases in Arf1, a GTP-binding protein, and AMPA receptors on the surface of rat neurons exposed to IFN suggest the mechanism of IFN neurotoxicity may relate to decreased Arf1 resulting in destabilization of dendritic spines, decreased PSD-95 expression, and internalization of AMPA receptors. Conclusion: B18R reversal of HAND in the mouse model is further evidence that the treatment of IFN in individuals with HAND could be a viable adjunctive treatment. Investigating pathways of IFN neurotoxicity may lead to more specific treatments.

AB - Objective: Increased brain interferon-alpha (IFN) is associated with neurodegenerative disorders, including HIV-associated neurocognitive disorders (HAND). HAND occurs in approximately 50% of individuals with HIV despite combined antiretroviral therapy (cART). Therefore, adjunctive therapies must be developed that prevent progression of mild forms of HAND to HIV-associated dementia. Increased IFN in the CNS has been associated with HAND in patients and in a HAND mouse model. Design and methods: B18R binds IFN and ameliorates HAND mouse brain histopathology (HIV encephalitis). The HAND model was used to determine if B18R with cART is superior to cART. Behavioral testing [Object recognition Test (ORT)] was used to show that B18R can reverse behavioral deficits. Rat neuronal cultures were used to investigate mechanisms of IFN neurotoxicity. Results: Mouse brain immunohistochemistry and densitometry suggests that B18R with a common cART regimen improve histopathological markers better than cART alone. B18R reverses ORT behavioral abnormalities in HAND mice. IFN-treated rat neurons show decreases in PSD-95, suggesting that dendritic spine architecture is disrupted. Decreases in Arf1, a GTP-binding protein, and AMPA receptors on the surface of rat neurons exposed to IFN suggest the mechanism of IFN neurotoxicity may relate to decreased Arf1 resulting in destabilization of dendritic spines, decreased PSD-95 expression, and internalization of AMPA receptors. Conclusion: B18R reversal of HAND in the mouse model is further evidence that the treatment of IFN in individuals with HAND could be a viable adjunctive treatment. Investigating pathways of IFN neurotoxicity may lead to more specific treatments.

KW - dendrites

KW - HIV-associated neurocognitive disorders

KW - interferon-alpha

KW - mouse model

KW - rat neuronal cultures

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85050244142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050244142&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001836

DO - 10.1097/QAD.0000000000001836

M3 - Article

VL - 32

SP - 1403

EP - 1411

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -